BridgeBio Pharma revenue and financials

BBIO · NASDAQ · USD

$65.99−0.23%−$0.16

Close · October 6, 2026

In the fiscal year ended December 2025, BridgeBio Pharma reported revenue of $502.08M (+126.26% year over year). The net loss was $732.94M.

Annual revenue · 2025: $502.08M

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	1,217	1,371	936	998	1,080	882	919	665	794	849	546	655
Current assets	1,093	1,241	798	839	912	695	721	445	616	783	478	588
Cash and equivalents	678	880	570	643	749	541	681	266	408	475	376	505
Short-term investments	42.2	60.3	17.4	3.0	7.9	—	—	—	39.8	44.5	58.9	38.1
Receivables	254	205	139	117	76.9	115	4.7	0.5	0.7	235	1.8	5.2
Inventory	52.8	33.0	26.8	24.5	18.3	4.0	—	—	—	—	—	—
Net property, plant and equipment	22.3	22.2	13.5	12.4	12.3	13.9	12.8	15.1	17.1	19.5	19.8	21.7
Other intangible assets	26.6	27.4	28.1	28.8	29.5	27.8	23.9	24.5	25.1	25.7	26.3	26.9
Long-term investments	55.1	61.5	80.0	92.2	108	128	144	160	117	—	1.6	0.5
Current liabilities	891	816	288	217	176	152	154	139	134	141	144	106
Accounts payable	27.2	29.1	36.2	18.7	26.1	27.5	9.6	13.4	18.1	4.7	10.7	4.5
Long-term debt	2,807	2,797	1,852	2,687	1,850	1,848	1,721	1,719	1,718	1,716	1,727	1,721
Total debt	2,494	2,492	1,862	1,860	1,858	—	—	—	—	—	—	—
Total liabilities	3,723	3,640	3,013	2,921	2,859	2,520	2,377	1,883	1,876	1,886	1,889	1,849
Total equity (incl. minority)	-2,506	-2,269	-2,077	-1,923	-1,778	-1,639	-1,458	-1,218	-1,082	-1,037	-1,343	-1,194
Retained earnings	-4,137	-3,985	-3,821	-3,628	-3,446	-3,264	-3,096	-2,831	-2,669	-2,596	-2,561	-2,392
Minority interest	9.3	9.5	10.0	10.3	9.4	9.7	10.3	11.5	10.8	12.7	11.7	13.8